- Report
- May 2023
- 220 Pages
Global
From €2291EUR$2,500USD£1,927GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2520EUR$2,750USD£2,119GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2520EUR$2,750USD£2,119GBP
- Report
- February 2022
- 210 Pages
Global
From €6873EUR$7,500USD£5,780GBP
- Report
- January 2022
- 90 Pages
Global
From €1833EUR$2,000USD£1,541GBP
- Report
- November 2023
- 181 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- December 2022
- 116 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- April 2023
- 115 Pages
Global
From €4353EUR$4,750USD£3,661GBP
- Report
- February 2024
- 120 Pages
Global
From €4353EUR$4,750USD£3,661GBP
- Report
- August 2022
- 111 Pages
Global
From €4353EUR$4,750USD£3,661GBP
- Report
- June 2022
- 120 Pages
Global
From €4353EUR$4,750USD£3,661GBP
- Report
- January 2022
- 122 Pages
Global
From €4353EUR$4,750USD£3,661GBP
- Report
- January 2025
- 85 Pages
India
From €3207EUR$3,500USD£2,697GBP
- Report
- September 2024
- 82 Pages
Japan
From €3207EUR$3,500USD£2,697GBP
- Report
- August 2024
- 80 Pages
Japan
From €3207EUR$3,500USD£2,697GBP
- Report
- May 2024
- 185 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- April 2024
- 190 Pages
Global
From €4124EUR$4,500USD£3,468GBP
- Report
- October 2022
- 82 Pages
Global
From €3203EUR$3,495USD£2,693GBP
- Report
- November 2021
- 108 Pages
Global
From €13742EUR$14,995USD£11,556GBP
- Report
- June 2021
Global
From €13742EUR$14,995USD£11,556GBP

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms.
Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients.
Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more